While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets. Market analysts and industry participants are closely tracking the development to assess its impact on consumer pricing, liquidity, and domestic business sentiment over the coming quarters.